You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Two studies, one positive and one negative, give proponents and skeptics more data to parse in debating whether genomically guided treatment has broad value in lung cancer.
The promising response rates seen in the SUMMIT trial may provide further reason to broadly test all advanced cervical cancer patients for precision medicine biomarkers.
Based on the expression of S100A2 and S100A4 proteins, researchers predicted which patients were likely to experience poor outcomes and disease recurrence post-surgery.
The new mutation may allow public health programs to refine inherited cancer risk screening for individuals in Brazil who also have the TP53-R337H mutation.
Use of the drug resulted in an encouraging response when an infant patient received it off-label in a first-line setting.
Despite recognition among drugmakers, researchers, and regulators of the need to diversify precision oncology trials, few Black and Hispanic patients are included in studies.
Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.
The findings underscore the utility of universal germline testing in young adults diagnosed with cancers that are more common in older populations.
As MacroGenics advances flotetuzumab through AML studies, it is working with researchers to refine the predictive ability of the gene expression signature.
In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors.